Skip to main content

Table 2 Patient characteristics for diagnosed gout and asymptomatic hyperuricemia

From: Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database

 

Total

(n = 276)

Age

0–5 years

(n = 22)

6–11 years

(n = 43)

12–18 years

(n = 211)

Age, years

 Median [Quartile]

15.0 [12.0, 17.0]

3.5 [2.0, 4.0]

9.0 [8.0, 11.0]

16.0 [14.0, 17.0]

Sex, n (%)

 Male

209 (75.7)

10 (45.5)

23 (53.5)

176 (83.4)

 Female

67 (24.3)

12 (54.5)

20 (46.5)

35 (16.6)

Comorbidity, n (%)

 Kidney disease

96 (34.8)

6 (27.3)

14 (32.6)

76 (36.0)

 Cardiovascular disease

63 (22.8)

9 (40.9)

15 (34.9)

39 (18.5)

 Metabolic syndrome

118 (42.8)

5 (22.7)

20 (46.5)

93 (44.1)

 Down syndrome

15 (5.4)

2 (9.1)

3 (7.0)

10 (4.7)

Treatment and drug use, n (%)

 Cardiovascular disease drug

9 (3.3)

0 (0.0)

5 (11.6)

4 (1.9)

 Diuretic drug

13 (4.7)

2 (9.1)

4 (9.3)

7 (3.3)

 β blocker

7 (2.5)

1 (4.5)

2 (4.7)

4 (1.9)

 Ca antagonist

8 (2.9)

0 (0.0)

1 (2.3)

7 (3.3)

 ACE inhibitor and/or ARB

32 (11.6)

1 (4.5)

6 (14.0)

25 (11.8)

 Antihyperlipidemic drug

14 (5.1)

0 (0.0)

0 (0.0)

14 (6.6)

 Antidiabetic drug

5 (1.8)

0 (0.0)

0 (0.0)

5 (2.4)

 Immunosuppressant

18 (6.5)

1 (4.5)

7 (16.3)

10 (4.7)

 Vitamin D

13 (4.7)

0 (0.0)

3 (7.0)

10 (4.7)

 Dialysis

2 (0.7)

0 (0.0)

0 (0.0)

2 (0.9)

 Treatment with uric acid lowering drug, n (%)

97 (35.1)

1 (4.5)

10 (23.3)

86 (40.8)

Number of measurement of sUA

 Median [Quartile]

2.0 [1.0, 4.0]

1.0 [0.0, 3.0]

3.0 [1.0, 6.0]

2.0 [1.0, 5.0]

Size of the facility, n (%)

 0–19 beds

113 (40.9)

3 (13.6)

11 (25.6)

99 (46.9)

 20–99 beds

6 (2.2)

1 (4.5)

0 (0.0)

5 (2.4)

 100–299 beds

31 (11.2)

2 (9.1)

4 (9.3)

25 (11.8)

  ≥ 300 beds

131 (47.5)

16 (72.7)

28 (65.1)

87 (41.2)

  1. ACE Angiotensin-converting enzyme, ARB Angiotensin II receptor blocker, sUA Serum uric acid